A trial platform to assess approved SARS-CoV-2 vaccines in immunocompromised patients: first sub-protocol for a pilot trial comparing the mRNA vaccines Comirnaty® and COVID-19 mRNA Vaccine Moderna®

BACKGROUND: Late 2019, a new highly contagious coronavirus SARS-CoV-2 has emerged in Wuhan, China, causing within 2 months a pandemic with the highest disease burden in elderly and people with pre-existing medical conditions. The pandemic has highlighted that new and more flexible clinical trial app...

Descripción completa

Detalles Bibliográficos
Autores principales: Speich, Benjamin, Chammartin, Frédérique, Smith, Daniel, Stoeckle, Marcel P., Amico, Patrizia, Eichenberger, Anna L., Hasse, Barbara, Schuurmans, Macé M., Müller, Thomas, Tamm, Michael, Dickenmann, Michael, Abela, Irene A., Trkola, Alexandra, Hirsch, Hans H., Manuel, Oriol, Cavassini, Matthias, Hemkens, Lars G., Briel, Matthias, Mueller, Nicolas J., Rauch, Andri, Günthard, Huldrych F., Koller, Michael T., Bucher, Heiner C., Kusejko, Katharina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8529365/
https://www.ncbi.nlm.nih.gov/pubmed/34674742
http://dx.doi.org/10.1186/s13063-021-05664-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8529365/
https://www.ncbi.nlm.nih.gov/pubmed/34674742
http://dx.doi.org/10.1186/s13063-021-05664-0

Ejemplares similares